StreetInsider.com News Articles

IQVIA Holdings (IQV) PT Lowered to $243 at Baird

Mon, 09 Mar 2026 06:19:11 -0400

Baird analyst Eric Coldwell lowered the price target on IQVIA Holdings (NYSE: IQV) to $243.00 (from $268.00) while maintaining a Outperform rating.

TD Cowen Upgrades IQVIA Holdings (IQV) to Buy

Mon, 09 Mar 2026 05:35:40 -0400

(Updated - March 9, 2026 5:35 AM EDT)

TD Cowen analyst Charles Rhyee upgraded IQVIA Holdings (NYSE: IQV) from Hold to Buy with a price target of $213.00 (from $174.00).

The analyst comments "We upgrade shares of IQV to Buy, from Hold, as we now believe AI is unlikely to lead to significant revenue H/Ws in RDS. This follows our panel at the TD Cowen 46th Health Care conference, where our experts (consisting of former CRO and large pharma R&D leaders) conducted a proprietary analysis of the impact of AI on outsourced clinical R&D spend. This analysis suggests AI is likely to

TD Cowen Upgrades IQVIA Holdings (IQV) to Buy

Mon, 09 Mar 2026 05:35:40 -0400

(Updated - March 9, 2026 5:35 AM EDT)

TD Cowen analyst Charles Rhyee upgraded IQVIA Holdings (NYSE: IQV) from Hold to Buy with a price target of $213.00 (from $174.00).

TD Cowen Upgrades IQVIA Holdings (IQV) to Buy

Mon, 09 Mar 2026 05:35:40 -0400

(Updated - March 9, 2026 5:35 AM EDT)

TD Cowen analyst Charles Rhyee upgraded IQVIA Holdings (NYSE: IQV) from Hold to Buy with a price target of $213.00 (from $174.00).

TD Cowen Upgrades IQVIA Holdings (IQV) to Buy

Mon, 09 Mar 2026 05:35:40 -0400

(Updated - March 9, 2026 5:35 AM EDT)

TD Cowen analyst Charles Rhyee upgraded IQVIA Holdings (NYSE: IQV) from Hold to Buy with a price target of $213.00 (from $174.00).

TD Cowen Upgrades IQVIA Holdings (IQV) to Buy

Mon, 09 Mar 2026 05:35:40 -0400

(Updated - March 9, 2026 5:35 AM EDT)

TD Cowen analyst Charles Rhyee upgraded IQVIA Holdings (NYSE: IQV) from Hold to Buy with a price target of $213.00 (from $174.00).

Barclays Upgrades IQVIA Holdings (IQV) to Overweight

Fri, 06 Mar 2026 06:18:34 -0400

(Updated - March 6, 2026 6:18 AM EST)

Barclays analyst Luke Sergott upgraded IQVIA Holdings (NYSE: IQV) from Equalweight to Overweight with a price target of $210.00.

The analyst comments "We upgrade IQV to Overweight and maintain our $210 price target. It is not without risk and we completely understand investor hesitance to fight an AI narrative that likely has no end in sight, as it is impossible to disprove a negative. However, we have mentioned before what IQV (and the rest of the complex) can do to give investors confidence and help backstop valuations (here). The first item is to give

Barclays Upgrades IQVIA Holdings (IQV) to Overweight

Fri, 06 Mar 2026 06:18:34 -0400

(Updated - March 6, 2026 6:18 AM EST)

Barclays analyst Luke Sergott upgraded IQVIA Holdings (NYSE: IQV) from Equalweight to Overweight with a price target of $210.00.

RBC Capital Starts IQVIA Holdings (IQV) at Outperform

Tue, 03 Mar 2026 02:01:17 -0400

RBC Capital analyst Ryan Halsted initiates coverage on IQVIA Holdings (NYSE: IQV) with a Outperform rating and a price target of $221.00.

The analyst comments: "We are initiating coverage of IQVIA at Outperform with a $221 price target given numerous data points suggesting an increase in clinical trial activity into 2026. We believe IQV is poised to benefit from this inflection in the CRO market relatively more than others based on its unique data analytics capabilities built with over 64 petabytes of data and competitive differentiation of strong existing relationships with large pharma. We view this proprietary data as the critical

RBC Capital Starts IQVIA Holdings (IQV) at Outperform

Tue, 03 Mar 2026 02:01:17 -0400

RBC Capital analyst Ryan Halsted initiates coverage on IQVIA Holdings (NYSE: IQV) with a Outperform rating and a price target of $221.00.

IQVIA CFO to Speak at Barclays 28th Annual Global Healthcare Conference

Mon, 02 Mar 2026 16:30:00 -0400

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Mike Fedock, executive vice president and chief financial officer, will speak at the Barclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026, at 9:30 a.m. ET.